Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent hospital readmissions and ER visits. The iUGO Care platform integrates wearables, sensors, voice technology and mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. The iUGO Care platform provides services, such as remote patient monitoring, chronic care management, principal care management, behavioral health integration, telemedicine, transitional care management, wound care, and others.


TSXV:RHT.H - Post by User

Comment by lscfaon Oct 08, 2024 11:51am
154 Views
Post# 36257935

RE:Form 52-109F1

RE:Form 52-109F1

Delay caused because mgmt does not want to report material weakness in MD&A so they are fixing it first before auditor signs off?


 

5.2         ICFR – material weakness relating to design: The issuer has disclosed in its annual MD&A for each material weakness relating to design existing at the financial year end

(a)          a description of the material weakness;

(b)          the impact of the material weakness on the issuer's financial reporting and its ICFR; and

(c)          the issuer's current plans, if any, or any actions already undertaken, for remediating the material weakness.

5.3         Limitation on scope of design: The issuer has disclosed in its annual MD&A

(a)          the fact that the issuer's other certifying officer(s) and I have limited the scope of our design of DC&P and ICFR to exclude controls, policies and procedures of

(i)           a proportionately consolidated entity in which the issuer has an interest;

(ii)          a special purpose entity in which the issuer has an interest; or

(iii)          a business that the issuer acquired not more than 365 days before the issuer's financial year end; and

(b)          summary financial information about the proportionately consolidated entity, special purpose entity or business that the issuer acquired that has been proportionately consolidated or consolidated in the issuer's financial statements.


https://www.osc.ca/en/securities-law/instruments-rules-policies/5/52-109/unofficial-consolidation-form-52-109f1-certification-annual-filings-full-certificate

<< Previous
Bullboard Posts
Next >>